ACTA1 and chronic kidney disease: Coherently, inhibition of Act-A signaling obtained by administration of soluble ActRIIA, or the use of a ligand trap, was effective in preventing muscle wasting in different mouse models of experimental CKD and promoted osteogenesis and increased bone mass in healthy mice and primates [57,58].